Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2015 |
| gptkbp:ATCCode |
gptkb:R03DX09
|
| gptkbp:brand |
gptkb:Nucala
|
| gptkbp:CASNumber |
gptkb:202825-46-5
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasMolecularFormula |
C6452H9954N1714O2016S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
mepolizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
fatigue
headache back pain injection site reaction |
| gptkbp:target |
gptkb:interleukin-5
|
| gptkbp:UNII |
4C9O2RII0E
|
| gptkbp:usedFor |
gptkb:eosinophilic_granulomatosis_with_polyangiitis
hypereosinophilic syndrome severe eosinophilic asthma |
| gptkbp:bfsParent |
gptkb:IL5
|
| gptkbp:bfsLayer |
6
|